Title:
NOVEL LRRK2 INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2022/216097
Kind Code:
A1
Abstract:
The present invention relates to: a novel leucine-rich repeat kinase 2 (LRRK2) inhibitor of chemical formula 1; a pharmaceutical composition containing same for preventing or treating LRRK2-mediated or -related diseases or disorders; and a method for treating and preventing diseases or disorders by using same. The compound according to the present invention has excellent LRRK2 inhibitory activity, and thus can be effectively used for preventing or treating LRRK2-mediated or -related diseases or disorders (for example, Parkinson's disease).
Inventors:
KANG EUNJI (KR)
KIM HYUN JIN (KR)
CHO DAE HYUN (KR)
LEE JAEYOUNG (KR)
KO EUN (KR)
KIM HYUN JIN (KR)
CHO DAE HYUN (KR)
LEE JAEYOUNG (KR)
KO EUN (KR)
Application Number:
PCT/KR2022/005074
Publication Date:
October 13, 2022
Filing Date:
April 07, 2022
Export Citation:
Assignee:
STANDIGM INC (KR)
International Classes:
C07D401/14; A61K31/506; A61K31/5377; A61P25/16; A61P25/28; C07D401/04; C07D401/12; C07D403/04; C07D403/14; C07D413/04
Foreign References:
| KR20160116033A | 2016-10-06 | |||
| KR20160002318A | 2016-01-07 | |||
| KR20140005882A | 2014-01-15 | |||
| KR20100015353A | 2010-02-12 | |||
| CN103483345A | 2014-01-01 |
Attorney, Agent or Firm:
RYU, Jong Woo et al. (KR)
Download PDF:
Previous Patent: NOVEL TARGET FOR ANTI-CANCER EFFECT AND IMMUNITY ENHANCEMENT
Next Patent: NOVEL LRRK2 INHIBITOR
Next Patent: NOVEL LRRK2 INHIBITOR